<DOC>
	<DOCNO>NCT01442064</DOCNO>
	<brief_summary>This open-label , multicenter , extension study intravitreally administer ranibizumab two cohort . The first cohort ( report separately FVF3426g , NCT00379795 ) enrol subject primary recurrent Choroidal Neovascularization ( CNV ) secondary Age-Related Macular Degeneration ( AMD ) complete treatment phase Genentech sponsor study ( FVF2598g ( NCT00056836 ) , FVF2587g ( NCT00061594 ) , FVF2428g ( NCT00056823 ) ) . The second cohort ( report ) enrol subject macular edema secondary Retinal Vein Occlusion ( RVO ) complete 6-month treatment 6-month observation phase ( 12 month total ) Genentech sponsor study ( FVF4165g ( NCT00486018 ) FVF4166g ( NCT00485836 ) ) . Patients enrol within 14 day completion previous study .</brief_summary>
	<brief_title>An Extension Study Evaluate Safety Tolerability Ranibizumab Macular Edema Secondary Retinal Vein Occlusion ( Cohort 2 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent form The 6month treatment 6month observation phase ( 12 month total ) Genentechsponsored ranibizumab study RVO ( FVF4165g FVF4166g ) Expectation investigator subject may potentially benefit intravitreal antivascular endothelial growth factor ( VEGF ) treatment History intraocular surgery ( include cataract extraction , scleral buckle , etc . ) within 1 month prior Day 0 extension study Concurrent use systemic antiVEGF agent Use RVO treatment approve Food Drug Administration ( FDA ) study eye Use intravitreal bevacizumab study eye and/or fellow eye Macular edema study eye due cause RVO diabetes History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye Uncontrolled glaucoma study eye ( defined intraocular pressure â‰¥ 30 mmHg despite treatment antiglaucoma medication ) Pregnancy lactation Premenopausal woman use adequate contraception History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Current treatment active systemic infection Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>CNV</keyword>
	<keyword>Lucentis</keyword>
	<keyword>AMD</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>RVO</keyword>
	<keyword>Macular edema secondary retinal vein occlusion</keyword>
</DOC>